Andrew Ross, Rebecca J Shaw, Louise Garth, Cathy Farrelly
{"title":"获得性FX缺乏的因子X浓缩治疗方案和剂量。","authors":"Andrew Ross, Rebecca J Shaw, Louise Garth, Cathy Farrelly","doi":"10.3390/hematolrep17020010","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acquired factor X (FX) deficiency is a rare condition that can cause life threatening bleeding. Here we outline a successful management strategy for gastrointestinal bleeding (GI) using human FX concentrate.</p><p><strong>Case description: </strong>A 61-year-old male presented with upper GI bleeding and a prolonged prothrombin time. Investigations demonstrated an acquired FX deficiency (determined to be secondary to AL amyloidosis).</p><p><strong>Results: </strong>Treatment with FX concentrate to maintain trough FX levels >20% resulted in successful cessation of bleeding symptoms, and levels >50% facilitated urgent invasive procedures.</p><p><strong>Conclusions: </strong>This case report adds valuable insight into the management of this rare condition, and how best to utilize FX concentrates in acquired FX deficiency.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"17 2","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932198/pdf/","citationCount":"0","resultStr":"{\"title\":\"Factor X Concentrate Treatment Schedule and Dosing in Acquired FX Deficiency.\",\"authors\":\"Andrew Ross, Rebecca J Shaw, Louise Garth, Cathy Farrelly\",\"doi\":\"10.3390/hematolrep17020010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Acquired factor X (FX) deficiency is a rare condition that can cause life threatening bleeding. Here we outline a successful management strategy for gastrointestinal bleeding (GI) using human FX concentrate.</p><p><strong>Case description: </strong>A 61-year-old male presented with upper GI bleeding and a prolonged prothrombin time. Investigations demonstrated an acquired FX deficiency (determined to be secondary to AL amyloidosis).</p><p><strong>Results: </strong>Treatment with FX concentrate to maintain trough FX levels >20% resulted in successful cessation of bleeding symptoms, and levels >50% facilitated urgent invasive procedures.</p><p><strong>Conclusions: </strong>This case report adds valuable insight into the management of this rare condition, and how best to utilize FX concentrates in acquired FX deficiency.</p>\",\"PeriodicalId\":12829,\"journal\":{\"name\":\"Hematology Reports\",\"volume\":\"17 2\",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932198/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/hematolrep17020010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hematolrep17020010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Factor X Concentrate Treatment Schedule and Dosing in Acquired FX Deficiency.
Background: Acquired factor X (FX) deficiency is a rare condition that can cause life threatening bleeding. Here we outline a successful management strategy for gastrointestinal bleeding (GI) using human FX concentrate.
Case description: A 61-year-old male presented with upper GI bleeding and a prolonged prothrombin time. Investigations demonstrated an acquired FX deficiency (determined to be secondary to AL amyloidosis).
Results: Treatment with FX concentrate to maintain trough FX levels >20% resulted in successful cessation of bleeding symptoms, and levels >50% facilitated urgent invasive procedures.
Conclusions: This case report adds valuable insight into the management of this rare condition, and how best to utilize FX concentrates in acquired FX deficiency.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
